Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus (HPV) based on pseudovirons

Journal of Medical Virology

Volumn 86, Issue 9, 2014, Pages 1542-1555

  Nie, Jianhui ^a,b   Huang, Weijin ^b   Wu, Xueling ^b   Wang, Youchun ^a,b  

^a JILIN UNIVERSITY   (China)

^b NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

Gaussia luciferase; Human papillomavirus; Neutralizing antibody

Indexed keywords

ALKALINE PHOSPHATASE; ALUMINUM HYDROXIDE; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G ANTIBODY; LUCIFERASE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; WART VIRUS VACCINE; ANTISERUM;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CELL COUNT; CONTROLLED STUDY; ENZYME IMMUNOASSAY; EXPERIMENTAL RABBIT; FEMALE; GAUSSIA LUCIFERASE GENE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; IC 50; INOCULATION; MOUSE; NONHUMAN; PLASMID; PSEUDOVIRION BASED NEUTRALIZATION ASSAY; REPORTER GENE; REPRODUCIBILITY; SECRETED ALKALINE PHOSPHATASE ASSAY; SENSITIVITY AND SPECIFICITY; STRUCTURAL GENE; VALIDATION STUDY; WART VIRUS; ANIMAL; BAGG ALBINO MOUSE; HEK293 CELL LINE; IMMUNIZATION; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; RABBIT; SERODIAGNOSIS; VIRION; VIROLOGY;

HUMAN PAPILLOMAVIRUS; ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; FEMALE; HEK293 CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNE SERA; IMMUNIZATION; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PAPILLOMAVIRUS INFECTIONS; RABBITS; SENSITIVITY AND SPECIFICITY; VIRION;

EID: 84904066595     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23995     Document Type: Article

References (43)

1. Amanna IJ, Carlson NE, Slifka MK. 2007. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357:1903-1915.
2. Badr CE, Hewett JW, Breakefield XO, Tannous BA. 2007. A highly sensitive assay for monitoring the secretory pathway and ER stress. PLoS ONE 2:e571.
3. Ball SL, Winder DM, Vaughan K, Hanna N, Levy J, Sterling JC, Stanley MA, Goon PK. 2011. Analyses of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol 83:1345-1350.
4. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70-79.
5. Buck CB, Thompson CD. 2007. Production of papillomavirus-based gene transfer vectors. Curr Protoc Cell Biol Chapter 26: Unit 26 21.
6. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2004. Efficient intracellular assembly of papillomaviral vectors. J Virol 78:751-757.
7. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS. 1996. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 224:477-486.
8. De Vincenzo R, Ricci C, Conte C, Scambia G. 2013. HPV vaccine cross-protection: Highlights on additional clinical benefit. Gynecol Oncol 130:642-651.
9. Ferguson M, Wilkinson DE, Heath A, Matejtschuk P. 2011. The first international standard for antibodies to HPV 16. Vaccine 29:6520-6526.
10. Ferlay JSH, Bray F, Forman D, Mathers C, Parkin DM. 2010. GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. Available at: http://globocan.iarc.fr.
11. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. 2012. Global burden of human papillomavirus and related diseases. Vaccine 30:F12-F23.
12. Kane MA, Serrano B, de Sanjose S, Wittet S. 2012. Implementation of human papillomavirus immunization in the developing world. Vaccine 30:F192-F200.
13. Kieback E, Muller M. 2006. Factors influencing subcellular localization of the human papillomavirus L2 minor structural protein. Virology 345:199-208.
14. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. 1994. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 86:494-499.
15. Klasse PJ, Sattentau QJ. 2002. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 83:2091-2108.
16. Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, Kanda T. 2007. Neutralization of HPV16, 18, 31 and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358:266-272.
17. Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T. 2008. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol 80:841-846.
18. Leder C, Kleinschmidt JA, Wiethe C, Muller M. 2001. Enhancement of capsid gene expression: Preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol 75:9201-9209.
19. Mascola JR, Louder MK, Winter C, Prabhakara R, De Rosa SC, Douek DC, Hill BJ, Gabuzda D, Roederer M. 2002. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J Virol 76:4810-4821.
20. Matumoto M. 1949. A note on some points of calculation method of LD50 by Reed and Muench. Jpn J Exp Med 20:175-179.
21. Meyer T, Arndt R, Christophers E, Beckmann ER, Schroder S, Gissmann L, Stockfleth E. 1998. Association of rare human papillomavirus types with genital premalignant and malignant lesions. J Infect Dis 178:252-255.
22. Mossadegh N, Gissmann L, Muller M, Zentgraf H, Alonso A, Tomakidi P. 2004. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology 326:57-66.
23. Nie J, Wang W, Wen Z, Song A, Hong K, Lu S, Zhong P, Xu J, Kong W, Li J, Shang H, Ling H, Ruan L, Wang Y. 2012. Optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China. J Virol Methods 185:267-275.
24. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E. 2007. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25:4931-4939.
25. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. 2003. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10:108-115.
26. Pagliusi SR, Teresa Aguado M. 2004. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23:569-578.
27. Palker TJ, Monteiro JM, Martin MM, Kakareka C, Smith JF, Cook JC, Joyce JG, Jansen KU. 2001. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine 19:3733-3743.
28. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kruger Kjaer S, Lowy DR, Schiller JT. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205-216.
29. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RB. 2005. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337:365-372.
30. Pastrana DV, Tolstov YL, Becker JC, Moore PS, Chang Y, Buck CB. 2009. Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog 5:e1000578.
31. Rizk RZ, Christensen ND, Michael KM, Muller M, Sehr P, Waterboer T, Pawlita M. 2008. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 89:117-129.
32. Roberts C, Swoyer R, Bryan J. 2012. Evaluation of the HPV 18 antibody response in Gardasil(R) vaccinees after 48 mo using a pseudovirion neutralization assay. Hum Vaccin Immunother 8:431-434.
33. Roden RB, Hubbert NL, Kirnbauer R, Breitburd F, Lowy DR, Schiller JT. 1995. Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol 69:5147-5151.
34. Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B, Descamps D. 2012. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: Up to 8.4 years of follow-up. Hum Vaccin Immunother 8:390-397.
35. Schiller JT, Castellsague X, Garland SM. 2012. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30:F123-F138.
36. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, Poncelet S, Zahaf T, Hardt K, Descamps D, Dubin G. 2009. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 27:581-587.
37. Sehr P, Rubio I, Seitz H, Putzker K, Ribeiro-Muller L, Pawlita M, Muller M. 2013. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS ONE 8:e75677.
38. Shank-Retzlaff M, Wang F, Morley T, Anderson C, Hamm M, Brown M, Rowland K, Pancari G, Zorman J, Lowe R, Schultz L, Teyral J, Capen R, Oswald CB, Wang Y, Washabaugh M, Jansen K, Sitrin R. 2005. Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples. Hum Vaccin 1:191-197.
39. Shank-Retzlaff ML, Zhao Q, Anderson C, Hamm M, High K, Nguyen M, Wang F, Wang N, Wang B, Wang Y, Washabaugh M, Sitrin R, Shi L. 2006. Evaluation of the thermal stability of Gardasil. Hum Vaccin 2:147-154.
40. Verhaegent M, Christopoulos TK. 2002. Recombinant Gaussia luciferase. Overexpression, purification, and analytical application of a bioluminescent reporter for DNA hybridization. Anal Chem 74:4378-4385.
41. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, Templin MF, Pawlita M. 2005. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 51:1845-1853.
42. Wu X, Zhang C, Feng S, Liu C, Li Y, Yang Y, Gao J, Li H, Meng S, Li L, Zhang Y, Hu X, Lin L, Li X, Wang Y. 2009. Detection of HPV types and neutralizing antibodies in Gansu province, China. J Med Virol 81:693-702.
43. Wu XL, Zhang CT, Zhu XK, Wang YC. 2010. Detection of HPV types and neutralizing antibodies in women with genital warts in Tianjin City, China. Virol Sin 25:8-17.